Modality
Radioligand
MOA
TYK2i
Target
CFTR
Pathway
DDR
ADHDCeliacBreast Ca
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
~Apr 2022
→ ~Jul 2023
Phase 2
Oct 2023
→ Oct 2028
Phase 2Current
NCT07886952
910 pts·ADHD
2025-11→2028-10·Terminated
NCT06161481
2,367 pts·Breast Ca
2023-10→TBD·Not yet recruiting
3,277 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-092.5y awayPh3 Readout· ADHD
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Not yet…
P2/3
Termina…
Catalysts
Ph3 Readout
2028-10-09 · 2.5y away
ADHD
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07886952 | Phase 2/3 | ADHD | Terminated | 910 | OS |
| NCT06161481 | Phase 2/3 | Breast Ca | Not yet recr... | 2367 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |